A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2
Dale, B. et al. Advancing targeted protein degradation for cancer therapy. Nat. Rev. Cancer 21, 638–654 (2021).
Google Scholar
Schapira, M., Calabrese, M. F., Bullock, A. N. & Crews, C. M. Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949–963 (2019).
Google Scholar
Samarasinghe, K. T. G. & Crews, C. M. Targeted protein degradation: a promise for undruggable proteins. Cell Chem. Biol. 28, 934–951 (2021).
Google Scholar
Békés, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022).
Google Scholar
Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611–617 (2015).
Google Scholar
Li, Z. et al. Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds. Nature 575, 203–209 (2019).
Google Scholar
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).
Google Scholar
Marei, H. et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature 610, 182–189 (2022).
Google Scholar
Zhou, Y. et al. Development of folate receptor targeting chimeras for cancer selective degradation of extracellular proteins. Nat. Commun. 15, 8695 (2024).
Google Scholar
Lu, P. et al. Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders. Cell 187, 7126–7142.e20 (2024).
Google Scholar
Buhimschi, A. D. et al. Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation. Biochemistry 57, 3564–3575 (2018).
Google Scholar
Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755–763 (2015).
Google Scholar
Han, X. et al. Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer. J. Med. Chem. 62, 941–964 (2019).
Google Scholar
Zeng, M. et al. Exploring targeted degradation strategy for oncogenic KRASG12C. Cell Chem. Biol. 27, 19–31.e6 (2020).
Google Scholar
Dong, G., Ding, Y., He, S. & Sheng, C. Molecular glues for targeted protein degradation: from serendipity to rational discovery. J. Med. Chem. 64, 10606–10620 (2021).
Google Scholar
Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301–305 (2014).
Google Scholar
Krönke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 523, 183–188 (2015).
Google Scholar
Han, T. et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science 356, eaal3755 (2017).
Google Scholar
Mayor-Ruiz, C. et al. Rational discovery of molecular glue degraders via scalable chemical profiling. Nat. Chem. Biol. 16, 1199–1207 (2020).
Google Scholar
Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature 535, 252–257 (2016).
Google Scholar
Ting, P. Y. et al. A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction. Science 385, 91–99 (2024).
Google Scholar
Clackson, T. et al. Redesigning an FKBP–ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl Acad. Sci. USA 95, 10437–10442 (1998).
Google Scholar
Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C. & Mayor-Ruiz, C. Chasing molecular glue degraders: screening approaches. Chem. Soc. Rev. 51, 5498–5517 (2022).
Google Scholar
Koduri, V. et al. Targeting oncoproteins with a positive selection assay for protein degraders. Sci. Adv. 7, eabd6263 (2021).
Google Scholar
Garber, K. The glue degraders. Nat. Biotechnol. 42, 546–550 (2024).
Google Scholar
Wang, Z., Liu, P., Inuzuka, H. & Wei, W. Roles of F-box proteins in cancer. Nat. Rev. Cancer 14, 233–247 (2014).
Google Scholar
Carrano, A. C., Eytan, E., Hershko, A. & Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1, 193–199 (1999).
Google Scholar
Liu, J. et al. Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. Cell Res. 31, 80–93 (2021).
Google Scholar
Chan, C. H. et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, Herceptin sensitivity, and tumorigenesis. Cell 151, 913–914 (2012).
Google Scholar
Huang, H. et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl Acad. Sci. USA 102, 1649–1654 (2005).
Google Scholar
Nakayama, K. et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication. EMBO J. 19, 2069–2081 (2000).
Google Scholar
Cai, Z. et al. The Skp2 pathway: a critical target for cancer therapy. Semin. Cancer Biol. 67, 16–33 (2020).
Google Scholar
Wang, G. et al. Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2. Oncogene 39, 7034–7050 (2020).
Google Scholar
Reichert, M., Saur, D., Hamacher, R., Schmid, R. M. & Schneider, G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res. 67, 4149–4156 (2007).
Google Scholar
Andreu, E. J. et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 65, 3264–3272 (2005).
Google Scholar
Sarmento, L. M. et al. Notch1 modulates timing of G1–S progression by inducing SKP2 transcription and p27Kip1 degradation. J. Exp. Med. 202, 157–168 (2005).
Google Scholar
Rodriguez, S. et al. Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL. Leukemia 34, 1241–1252 (2020).
Google Scholar
Zhang, S. et al. Hippo signaling suppresses cell ploidy and tumorigenesis through Skp2. Cancer Cell 31, 669–684.e7 (2017).
Google Scholar
Wei, W. et al. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 428, 194–198 (2004).
Google Scholar
Connell, P. et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 3, 93–96 (2001).
Google Scholar
Xu, W. et al. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl Acad. Sci. USA 99, 12847–12852 (2002).
Google Scholar
Schulman, B. A. et al. Insights into SCF ubiquitin ligases from the structure of the Skp1–Skp2 complex. Nature 408, 381–386 (2000).
Google Scholar
Mercer, J. A. M. et al. Continuous evolution of compact protein degradation tags regulated by selective molecular glues. Science 383, eadk4422 (2024).
Google Scholar
Ma, D. et al. A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer. Theranostics 10, 3708–3721 (2020).
Google Scholar
Xu, W. et al. Compartmentalization-aided interaction screening reveals extensive high-order complexes within the SARS-CoV-2 proteome. Cell Rep. 36, 109482 (2021).
Google Scholar
Bennett, J. L., Nguyen, G. T. H. & Donald, W. A. Protein–small molecule interactions in native mass spectrometry. Chem. Rev. 122, 7327–7385 (2022).
Google Scholar
Chan, C. H. et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154, 556–568 (2013).
Google Scholar
Wang, S. T., Ho, H. J., Lin, J. T., Shieh, J. J. & Wu, C. Y. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 8, e2626 (2017).
Google Scholar
Su, J., Zhou, X., Wang, L., Yin, X. & Wang, Z. Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cells. Am. J. Cancer Res. 6, 1949–1962 (2016).
Google Scholar
Huang, H. C., Way, T. D., Lin, C. L. & Lin, J. K. EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein. Endocrinology 149, 5972–5983 (2008).
Google Scholar
Yang, E. S. & Burnstein, K. L. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol. Chem. 278, 46862–46868 (2003).
Google Scholar
Elahi, A. H. et al. Targeted pharmacologic inhibition of S-phase kinase-associated protein 2 (SKP2) mediated cell cycle regulation in lung and other RB-related cancers: a brief review of current status and future prospects. Adv. Biol. Regul. 88, 100964 (2023).
Google Scholar
Zhao, H. et al. Targeted inhibition of the E3 ligase SCFSkp2/Cks1 has antitumor activity in RB1-deficient human and mouse small-cell lung cancer. Cancer Res. 80, 2355–2367 (2020).
Google Scholar
Jerabek-Willemsen, M., Wienken, C. J., Braun, D., Baaske, P. & Duhr, S. Molecular interaction studies using microscale thermophoresis. Assay Drug Dev. Technol. 9, 342–353 (2011).
Google Scholar
Chu, Y. et al. A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2. Mendeley Data https://data.mendeley.com/datasets/vnbpprr393/1 (2025).
